Johnson & Johnson's SWOT analysis: stock outlook amid oncology growth and challenges

Johnson & Johnson reported strong Q1 2025 results, driven by a 4.4% increase in its Innovative Medicine segment, particularly in oncology with products like DARZALEX, which is projected to reach $11.6 billion in sales by 2024. While the MedTech segment experienced slower growth at 1.3%, the company faces challenges including the loss of exclusivity for Stelara, expected to impact sales by $2 billion; however, the acquisition of ITCI is viewed positively and JNJ maintains its 2025 guidance, targeting 5-7% operational growth from 2025 to 2030.

Analysis

Johnson & Johnson (JNJ) demonstrated resilience in Q1 2025, reporting adjusted operational sales growth of 3.3% year-over-year, surpassing estimates, primarily driven by a 4.4% increase in its Innovative Medicine segment. Within this segment, oncology remains a significant growth engine, with key products like DARZALEX projected to achieve $11.6 billion in sales by 2024, and CARVYKTI and TECVAYLI showing a combined peak year sales potential exceeding $5 billion; JNJ ambitiously targets oncology sales to triple to over $50 billion by 2030. Conversely, the MedTech segment exhibited more modest growth at 1.3% year-over-year, with noted underperformance in Orthopedics and Electrophysiology attributed to competitive pressures. The company faces material headwinds, including an approximate $2 billion sales impact from the loss of exclusivity (LOE) for Stelara and the Part D redesign, alongside persistent talc litigation risks. Despite these challenges, management has maintained its 2025 guidance and aims for 5-7% operational Long Range Plan growth from 2025 to 2030. The recent acquisition of ITCI is viewed by analysts as a positive long-term contributor, expected to become accretive post-2026. Analyst sentiment is mixed, with RBC Capital Markets maintaining an "Outperform" rating and a $181.00 price target, while Barclays holds an "Equal Weight" rating with price targets around $165.00-$166.00, reflecting a cautious optimism contingent on navigating upcoming challenges.

Key Decisions for Investors

• Investors should closely monitor JNJ's ability to execute on its ambitious oncology growth targets, particularly the projected tripling of sales by 2030, as this is a key pillar for future value creation.
• Careful assessment of the MedTech segment's performance is warranted, specifically looking for signs of recovery in underperforming areas like Orthopedics and Electrophysiology, and the company's strategies to mitigate competitive pressures.
• The financial impact of Stelara's loss of exclusivity, estimated at $2 billion, and the progress of integrating the ITCI acquisition, particularly its timeline to accretion post-2026, are critical factors to track for their effect on JNJ's guided 5-7% long-range operational growth.